Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company, which makes technology that can read the genetic information of the human immune system, increased its target price to $18 to $19 per share and could raise as much as $327.5 million from investors, according to a new SEC filing.
That haul would value Adaptive at more than $2 billion when the company debuts on the tech-heavy NASDAQ exchange under the ticker ADPT on Thursday.
Image: Adaptive Biotechnologies co-founder and CEO Chad Robins speaks at the 2018 GeekWire Summit. (GeekWire Photo / Kevin Lisota)
